Skip to content

Esperion Therapeutics ESPR Unrealized Losses on Investments (Before Tax)

Unrealized Losses on Investments (Before Tax) at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$32K
Amgen logo
AmgenAMGN
BridgeBio Pharma logo
BridgeBio PharmaBBIO
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
Absci Corporation logo
Absci CorporationABSI

Other financials

Income statement

See full
Revenue$80.1M+23.2%
Operating income-$6.6M+70.2%
Net income-$25.2M+37.7%
EPS (diluted)-$0.10+52.4%

Balance sheet

See full
Cash & equivalents$156.2M+36.2%
Total debt$155.2M+6.1%
Total equity-$307.9M+27.8%
Total assets$462.5M+42.7%

Cash flow

See full
Operating cash flow-$27.7M-22.5%
CapEx$189.0K
Free cash flow-$27.9M-23.3%

Valuation

See full
Market cap$811.73M+283%
Enterprise value$810.81M+233%
P/S1.9×+1.1×

Profitability

See full
Operating margin18.1%+12.7pp
Net margin-34.8%+8.0pp
FCF margin-30.7%

Returns & leverage

See full
Return on equity-260.8%
Debt / equity0.8×
Current ratio1.5×+0.4×

Where this comes from

Reported directly by Esperion Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.

The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Esperion Therapeutics's unrealized losses on investments (before tax).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Esperion Therapeutics's unrealized losses on investments (before tax)?
Esperion Therapeutics (ESPR) reported unrealized losses on investments (before tax) of $0 in Q1 2026.
What does unrealized losses on investments (before tax) mean?
This represents the cumulative decrease in the fair market value of investment securities held by the company that have not yet been sold, measured before tax effects. It highlights the potential volatility and risk exposure within the company's investment portfolio. Investors monitor this to gauge the impact of market fluctuations on the company's balance sheet.